Last $0.0020 USD
Change Today 0.0001 / 5.26%
Volume 2.3M
BIEL On Other Exchanges
Symbol
Exchange
OTC US
As of 11:13 AM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

bioelectronics corp (BIEL) Snapshot

Open
$0.0019
Previous Close
$0.0019
Day High
$0.0020
Day Low
$0.0018
52 Week High
02/24/14 - $0.0084
52 Week Low
02/4/14 - $0.0002
Market Cap
4.9M
Average Volume 10 Days
13.6M
EPS TTM
--
Shares Outstanding
2.4B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOELECTRONICS CORP (BIEL)

Related News

No related news articles were found.

bioelectronics corp (BIEL) Related Businessweek News

No Related Businessweek News Found

bioelectronics corp (BIEL) Details

BioElectronics Corporation develops, manufactures, and markets drug–free, topical pain medical devices. Its products comprise ActiPatch therapy for over-the-counter treatment of back pain and other musculoskeletal complaints; Allay menstrual cycle pain therapy; RecoveryRx for chronic and post-operative wound care; and HealFast therapy, a drug-free therapy for healing of muscle and tendon injuries, sores, and incision in horses, cats, and dogs. The company markets and sells its products under the ActiPatch, Allay, and RecoveryRx brand names through distributors primarily in Korea, Singapore, Malaysia, Canada, Columbia, Scandinavia, Saudi Arabia, the Balkans, Australia, China, and South America. BioElectronics Corporation was founded in 2000 and is based in Frederick, Maryland.

bioelectronics corp (BIEL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

bioelectronics corp (BIEL) Key Developments

Bioelectronics Corporation Announces Interim Results of Placebo Controlled Trial on Osteoarthritis of the Knee Using ActiPatch(R) Therapy

BioElectronics Corporation announced more detail on the interim results of a randomized, double blind, placebo controlled trial on osteoarthritis of the knee (knee pain) using ActiPatch(R) Therapy. Arthritis is the major cause of disability in the US affecting 52.5 million adults. Osteoarthritis of the knee is the most common musculoskeletal pain and disability condition. Therefore it are extremely pleased by the results of Dr. Gianluca Bagnato's clinical study. ActiPatch(R) Musculoskeletal Pain Therapy devices are readily available, over-the-counter outside of the US, for approximately $30.00, or $0.04 per hour of therapy. The specific four weeks of ActiPatch(R) Therapy showed the following: Patients treated with ActiPatch(R) Therapy showed a statistically significant improvement in visual analogue pain scores (VAS) (p<0.005) and WOMAC pain scores (p<0.001) at 4 weeks compared to baseline. Patients treated with ActiPatch(R) Therapy assessed for function and disability showed statistically significant improvement for WOMAC function (p<0.002) and WOMAC stiffness (p<0.02) at 4 weeks compared to baseline. Patients treated with ActiPatch(R) Therapy also demonstrated statistically significant (p<0.04) improved physical and mental health as assessed by the SF-36 (36-item Medical Outcomes Study Short-Form 36 version 2) at 4 weeks compared to baseline. No statistically significant results were recorded in the placebo group.

Bioelectronics Corporation Enters into Distribution Agreement Biomax, Inc. and One Globe Biotechnology LLC

BioElectronics Corporation announced that Biomax, Inc. and One Globe Biotechnology LLC will exclusively distribute ActiPatch(R) and Allay(R) Therapy to Austria's population of over eight million. Biomax, Inc. and One Globe Biotechnology LLC are the exclusive distributors of the entire line of BioElectronics products in Italy.

BioElectronics Appoints Deepak Kotak as Executive Vice President

BioElectronics Corporation has appointed Dr. Deepak Kotak MA (Oxford), MBBS, FRCA, MRCP, LLDip, LLM as Executive Vice President. With the appointment of Dr. Kotak who lives in London, BioElectronics will have a greater presence in Europe to further promote the ActiPatch Therapy product line that is available OTC in Boots. Prior to his appointment, Dr. Kotak has been Chief Medical Officer of TraumaTec, a Houston medical device company as well as a consultant to the Boss Group and Blackstone Valley Group, two private equity firms.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIEL:US $0.00 USD 0.0001

BIEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIEL.
View Industry Companies
 

Industry Analysis

BIEL

Industry Average

Valuation BIEL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOELECTRONICS CORP, please visit www.bielcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.